2
H index
0
i10 index
9
Citations
Grace Hampson : Citation Profile
Office of Health Economics | RESEARCH PRODUCTION: 4 Articles 15 Papers RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
4 years (2015 - 2019). Relations with other researchers
Works with:
Authors registered in RePEc who have co-authored more than one work in the last five years with Grace Hampson. | Is cited by:
| Cites to:
|
Main data
Where Grace Hampson has published?
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Research Papers / Office of Health Economics | 7 |
| Consulting Reports / Office of Health Economics | 4 |
| Briefings / Office of Health Economics | 4 |
Recent works citing Grace Hampson (2020 and 2019)
| Year | Title of citing document |
|---|---|
| 2020 | Complexity Stage Model of the Medical Device Development Based on Economic Evaluation—MedDee. (2020). Peter, Luka ; Mareova, Petra ; Kua, Kamil ; Klimova, Blanka ; Mohelska, Hana ; Augustnek, Martin ; Penhaker, Marek ; Ren, Luka ; Honegr, Jan. In: Sustainability. RePEc:gam:jsusta:v:12:y:2020:i:5:p:1755-:d:325509. Full description at Econpapers || Download paper |
| 2019 | Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance. (2019). Crispi, Francisca ; Mossialos, Elias ; Osipenko, Leeza ; Barkauskaite, Eva ; Naci, Huseyin. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:17:y:2019:i:2:d:10.1007_s40258-018-0438-y. Full description at Econpapers || Download paper |
| 2020 | Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment. (2020). Gonalves, Elisabete. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:21:y:2020:i:3:d:10.1007_s10198-019-01147-x. Full description at Econpapers || Download paper |
| 2019 | Spillover Effects on Caregivers’ and Family Members’ Utility: A Systematic Review of the Literature. (2019). Wittenberg, Eve ; Prosser, Lisa A ; James, Lyndon P. In: PharmacoEconomics. RePEc:spr:pharme:v:37:y:2019:i:4:d:10.1007_s40273-019-00768-7. Full description at Econpapers || Download paper |
Works by Grace Hampson:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2016 | New Age Decision Making in HTA: Is It Applicable in Asia? In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2017 | How can HTA meet the needs of health system and government decision makers? In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Transferability of HTA In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2016 | Four Case Studies to Explore the Added Value of Oxford AHSN In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose? In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
| 2019 | Public Preferences for Health Gains and Cures: A Discrete Choice Experiment In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2015 | Dementia: The R&D Landscape In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2016 | A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications In: Research Papers. [Full Text][Citation analysis] | paper | 2 |
| 2016 | Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).(2018) In: PharmacoEconomics - Open. [Full Text][Citation analysis] This paper has another version. Agregated cites: 0 | article | |
| 2017 | Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value In: Research Papers. [Full Text][Citation analysis] | paper | 1 |
| 2017 | Macro Evaluation of the NIHR Oxford Biomedical Research Centre In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Real World Evidence for Coverage Decisions: Opportunities and Challenges In: Research Papers. [Full Text][Citation analysis] | paper | 1 |
| 2018 | Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2017 | What Determines the Health Care Expenditure of High Income Countries? A Dynamic Estimation In: Applied Economics and Finance. [Full Text][Citation analysis] | article | 0 |
| 2017 | A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 3 |
| 2019 | Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 1 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated July, 2 2020. Contact: CitEc Team